Media.nature.com

Currently, there is no active treatment available for this group of patients. Lenvatinib is proposed to be used in patients who progress after treatment with radioactive iodine. In November 2015, the PBAC agreed that there was a clinical need for an effective treatment for symptomatic, rapidly progressing patients with RAI-R DTC. Comparator ................
................